Table 1.
Characteristics of IPF patients included in COFI cohort according to gender.
| Patients with Idiopathic pulmonary fibrosis N = 246 | Women n = 51 | Men n = 185 | P-value |
|---|---|---|---|
| Age (years): mean ± SD | 70.1 ± 9.2 | 67.4 ± 10.9 | 0.08 |
| Age ≥ 65 years old:n (%) | 40 (78%) | 112 (61%) | 0.028 |
| BMI: mean ± SD | 27.2 ± 4.70 | 27.5 ± 4.19 | 0.697 |
| Smoking history:n (%) | <0.001 | ||
| Current | 1 (2%) | 15 (8%) | |
| Former | 18 (35%) | 131 (71%) | |
| Never | 32 (63%) | 39 (21%) | |
| Occupational exposures:n (%) | 0.012 | ||
| At least one exposurea | 7 (14%) | 63 (34%) | |
| Comorbidities:n (%) | |||
| GastroEsophageal reflux | 15 (29%) | 52 (28%) | 0.994 |
| Ischemic heart disease | 5 (10%) | 36 (20%) | 0.081 |
| Arterial hypertension | 31 (61%) | 96 (52%) | 0.161 |
| Diabetes | 9 (18%) | 42 (23%) | 0.559 |
| Venous thromboembolic events | 6 (12%) | 4 (2%) | 0.008 |
| Osteoporosis | 5 (10%) | 4 (2%) | 0.025 |
| Sleep apnoea | 3 (6%) | 27 (15%) | 0.157 |
| NYHA functional class at inclusion:n (%) | 0.206 | ||
| Class III–IV | 16 (31%) | 40 (22%) | |
| Crackles at inclusion:n (%) | 50 (98%) | 175 (95%) | 0.464 |
| Auto immune features at inclusion:n (%) | 0.628 | ||
| At least one positive auto antibodyb | 24 (47%) | 77 (42%) | |
| CT features at inclusion:n (%) | |||
| Honeycombing | 40 (78%) | 167 (90%) | 0.041 |
| Emphysema | 6 (12%) | 48 (26%) | 0.029 |
| PFTs at inclusion | |||
| TLC (ml): mean ± SD | 3.238 ± 878 | 4.564 ± 1.110 | <0.001 |
| TLC (% predicted): mean ± SD | 69.8 ± 18.3 | 69.1 ± 15.6 | 0.821 |
| FVC (ml): mean ± SD | 1.864 ± 572 | 2.820 ± 778 | <0.001 |
| FVC (% predicted): mean ± SD | 83.0 ± 25.0 | 75.4 ± 18.7 | 0.046 |
| FEV1(ml): mean ± SD | 1.551 ± 487 | 2.327 ± 598 | <0.001 |
| FEV1 (% predicted): mean ± SD | 84.3 ± 26.3 | 81.0 ± 19.4 | 0.406 |
| DLCO (mmol/min/kPa): mean ± SD | 3.81 ± 3.10 | 6.56 ± 7.20 | 0.004 |
| DLCO (% predicted): mean ± SD | 45.8 ± 15.1 | 48.3 ± 18.2 | 0.341 |
| 6MWT at inclusion | |||
| Distance (m): mean ± SD | 356 ± 132 | 428 ± 113 | 0.001 |
| Distance (% predicted): mean ± SD | 77.7 ± 27.7 | 80.5 ± 21.5 | 0.553 |
| Desaturation <88%: n (%) | 21 (53%) | 84 (50%) | 0.806 |
| Follow-up | |||
| Number of hospitalizations: mean ± SD | 1.33 ± 1.90 | 1.12 ± 1.74 | 0.457 |
| Acute exacerbation: n (%) | 6 (12%) | 27 (15%) | 1.000 |
| Death: n (%) | 32 (63%) | 104 (58%) | 0.813 |
| Transplantation: n (%) | 1 (2%) | 20 (11%) | 0.039 |
a
asbestos, crystalline silica, wood, organic, livestock, and metal dust.
b
Antinuclear antibodies, rheumatoid factor, myositis panel, and anti–cyclic citrullinated peptide, antineutrophil cytopasmic autoantibodies.
SD, Standard deviation; BMI, body mass index; CT, computed tomography; PFTs, pulmonary function tests; TLC, total lung capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; DLCO, diffusing capacity of the lung for carbon monoxide; 6MWT, six-minute walk test.
The values in bold are below the significance level of 0.05.